Acomplia is metabolized in the liver mostly. High level of binding Rimonabant to plasma proteins (99,9%) provides Acomplia with high grade of pharmacological activity.

The results of clinical studies have proven that Rimonabant better distributed within the body of the obese patients, than in patients with normal body weight.

About 3% of dose Acomplia (Rimonabant) is excreted with urine, and about 86% of dose Acomplia is excreted unchanged (metabolites) with feces.